Mylan Sells Entire Biocon Stake for Rs 3,679 Crore

Mylan Inc., a subsidiary of global healthcare company Viatris, has divested its entire 5.64% stake in

through open market transactions. According to bulk and block deal disclosures on the BSE and NSE, the company sold a total of 91.97 million equity shares. The shares were split almost equally between the two exchanges and were transacted at an average price of ₹400 per share. The stake sale was valued at approximately ₹3,679 crore, marking Mylan's complete exit from its investment in Biocon. A large institutional stake sale can create short-term pressure on the stock due to the increased supply of shares. However, if the sale is driven by the investor's portfolio strategy rather than company-specific concerns and is comfortably absorbed by the market, it may indicate sustained institutional demand and have limited impact on the company's long-term fundamentals. Disclaimer: This update is provided for informational and educational purposes only and should not be construed as investment advice or a recommendation to buy, sell, or hold any security. Investors should conduct their own research and consider their financial objectives and risk tolerance before making any investment decisions. Past performance is not indicative of future results.